Comparison between patients who achieved disease control and those who did not achieve disease control
| Achieved disease control (n=8) | Did not achieve disease control (n=32) | P value | |
| Men:women | 1:7 | 5:27 | 0.9 |
| Age at disease diagnosis, median (IQR), years | 14.2 (11.3–15.2) | 14.3 (11.3–16.5) | 0.9 |
| Age at first RTX use, median (IQR), years | 17.5 (15.4–19.9) | 21.2 (17.1–28.3) | 0.06 |
| Interval of first RTX after diagnosis, median (IQR), years | 2.1 (0.2–8.5) | 7.8 (2.9–13.1) | 0.02* |
| Number of times of RTX administrations, mean (SD) | 2.9 (2) | 3.4 (2) | 0.6 |
| SLEDAI-2K before RTX, median (IQR) | 8 (5–20) | 8 (6–12) | 0.6 |
| SLEDIA-2K 2 years after RTX, median (IQR) | 2 (1–2) | 6 (4–8) | <0.01* |
| Year of diagnosis, median (IQR) | 2012 (2007–2018) | 2015 (2006–2019) | 0.8 |
| Duration of follow-up, median (IQR), years | 2.2 (1.2–4.4) | 2.9 (2.5–4.5) | 0.6 |
*p<0.05.
RTX, rituximab; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.